INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 45h ago
HOUSE PTR5h ago
SEC 13F5h ago
ROBINHOOD CHAIN5h ago
Corporate insider
BL

Burrows Scott L

Chief Financial OfficerCIK 0001853327

EDGAR filingsOpen in network
Disclosed transactions8
Buys / sells0 / 3
Max Insider Score27
Connections1with evidence

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
23
BL
Burrows Scott LChief Financial Officer
SYRESpyre Therapeutics, Inc.
Open-market sale
SELL$436K
5,000 sh
Jun 25, 2026Jun 26, 2026
traded Jun 25, 2026
+1dSEC FORM 4

Evidence

Verified connections

  • Insider ofevidence
    Spyre Therapeutics, Inc.Chief Financial Officer · Jan 13, 2026
5
BL
Burrows Scott LChief Financial Officer
SYRESpyre Therapeutics, Inc.
Option exercise
M
—
15.0K sh
Jun 25, 2026
Jun 26, 2026
traded Jun 25, 2026
+1d
SEC FORM 4

Evidence

27
BL
Burrows Scott LChief Financial Officer
SYRESpyre Therapeutics, Inc.
Open-market sale
SELL$871K
10.0K sh
Jun 25, 2026Jun 26, 2026
traded Jun 25, 2026
+1dSEC FORM 4

Evidence

12
BL
Burrows Scott LChief Financial Officer
SYRESpyre Therapeutics, Inc.
Option exercise
M$218K
15.0K sh
Jun 25, 2026Jun 26, 2026
traded Jun 25, 2026
+1dSEC FORM 4

Evidence

6
BL
Burrows Scott LChief Financial Officer
SYRESpyre Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$181K
12.5K sh
May 1, 2026May 1, 2026
traded May 1, 2026
+0dSEC FORM 4

Evidence

20
BL
Burrows Scott LChief Financial Officer
SYRESpyre Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$892K
12.5K sh
May 1, 2026May 1, 2026
traded May 1, 2026
+0dSEC FORM 4

Evidence

0
BL
Burrows Scott LChief Financial Officer
SYRESpyre Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
12.5K sh
May 1, 2026May 1, 2026
traded May 1, 2026
+0dSEC FORM 4

Evidence

9
BL
Burrows Scott LChief Financial Officer
SYRESpyre Therapeutics, Inc.
Grant or award
A—
140.0K sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC FORM 4

Evidence